Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Research analysts at HC Wainwright increased their FY2027 earnings per share estimates for shares of Eton Pharmaceuticals in a report released on Monday, January 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $1.27 for the year, up from their prior forecast of $1.25. HC Wainwright currently has a "Buy" rating and a $17.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals' FY2028 earnings at $1.62 EPS and FY2029 earnings at $2.31 EPS.
Separately, Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday.
Check Out Our Latest Report on Eton Pharmaceuticals
Eton Pharmaceuticals Stock Up 0.2 %
Shares of Eton Pharmaceuticals stock traded up $0.02 during trading hours on Wednesday, reaching $12.01. 322,296 shares of the stock traded hands, compared to its average volume of 259,796. The company has a 50 day moving average price of $11.57 and a 200 day moving average price of $7.32. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $15.00. The firm has a market capitalization of $312.87 million, a price-to-earnings ratio of -54.59 and a beta of 1.38.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Eton Pharmaceuticals in the 3rd quarter worth $54,000. Jane Street Group LLC purchased a new stake in shares of Eton Pharmaceuticals during the third quarter worth about $90,000. Renaissance Technologies LLC raised its stake in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company's stock valued at $350,000 after purchasing an additional 41,469 shares during the period. Stonepine Capital Management LLC purchased a new position in Eton Pharmaceuticals in the 2nd quarter worth approximately $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company's stock worth $390,000 after purchasing an additional 30,167 shares during the period. 27.86% of the stock is owned by hedge funds and other institutional investors.
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
See Also
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
